The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
美國食品藥品管理局批准了 C4 Therapeutics 針對非小細胞肺癌的 CFT8919 的研究性新藥申請；在貝達製藥完成大中華區 1 期劑量遞增研究後，C4T 預計將在大中華區以外啓動試驗
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
美國食品藥品管理局批准了 C4 Therapeutics 針對非小細胞肺癌的 CFT8919 的研究性新藥申請；在貝達製藥完成大中華區 1 期劑量遞增研究後，C4T 預計將在大中華區以外啓動試驗